You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康恩貝(600572.SH):子公司洋常春藤葉提取物及口服液獲得藥物臨牀試驗批准通知書
格隆匯 11-27 16:25

格隆匯11月27日丨康恩貝(600572.SH)公佈,控股79.839%的子公司浙江康恩貝中藥有限公司收到國家藥品監督管理局核准簽發的洋常春藤葉提取物及口服液的《藥物臨牀試驗批准通知書》。康恩貝中藥公司申請藥物臨牀試驗的洋常春藤葉口服液,適應症為急性氣管、支氣管炎引起的咳嗽、痰多,給藥途徑為口服給藥,註冊分類屬中藥1.2類新藥。最適用法用量待臨牀試驗結束後確認。本品已開展的藥效學和藥代動力學動物實驗結果表明,洋常春藤葉提取物具有鎮咳、祛痰、平喘、抗炎、增強免疫的功效。截至目前,康恩貝中藥公司對本品已投入研發費用約人民幣1,570萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account